TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Incidence of Grade 3 or 4 drug related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of PRL3-zumab
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase 2 Dose (RP2D) of PRL3-zumab
Endpoint domain: Adverse events/effects
Primary endpoint: Change in daily physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Functional assessments
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: First Pass Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Absence of clinically driven target lesion revascularization (CDTLR) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of death from cardiovascular origin
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of major amputation of target limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Subjects Reporting Solicited Local Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects Reporting Solicited General Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects Reporting Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Serum PK parameters for CUE-101
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's Yale Brown Obsessive Compulsive Scale (CYBOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Developed Non-Melanoma Skin Cancer (NMSC)
Endpoint domain: Adverse events/effects
Primary endpoint: Hemorrhagic complication
Endpoint domain: Adverse events/effects
Primary endpoint: Evolution of renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Complete-remission rate after induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychosocial Impact of Assistive Devices Scale (PIADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cleanliness Scale
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Rapid Visual Information Processing performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Procedure related pain/discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum pain during procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visibility of the membrane after injection of the dye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of transient bacteremia and established blood-stream infections (BSIs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in the concentration of inflammatory mediator metabolites in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Use of intrauterine contraception at 6 months post abortion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: R0 Resection Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Anterior Chamber Cell Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endodontic Treatment survival
Endpoint domain: Mortality/survival
Primary endpoint: Need for new intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Blood glucose, HbA1c%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity of MRI and DWI for prostate cancer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of MRI and DWI for prostate cancer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy of MRI and DWI for prostate cancer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Brain Boundary Shift Integral (BBSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Hippocampus Volume Average Percent (%) Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Fractional Anisotropy (FA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Mean Diffusivity (MD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Psychomotor outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durable Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Symptomatic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to physical activity prescription
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Asthma or COPD hospitalizations or emergency department visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Oxygen enhanced MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak exercise pulmonary oxygen uptake (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5hmc expression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID-19 clinical course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, nature, and severity of adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic parameters of GDC-0623
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fresher breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD symptom level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of live Lactobacillus Reuteri ATC PTA 4659 in faecal material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diarrhoea remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life by QLQ-C30 and QLQ-OV28
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of subjects with treatment completion at day 28
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: A-a gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Patients With ALT >=3x ULN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Incidence of Hy's Law
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: full adherence to iron supplements
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of Clinically Significant Osteolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: patency of a biliary stent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in sleep architecture
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in ALS Functional Rating Score (ALSFRS-R slope)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf) of RSG XR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of RSG XR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful ECMO blood flow reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Depression levels among mothers
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Optic nerve head pressure-flow relationship
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: treatment response to ledipasvir/sofosbuvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with inhalation devices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perpetration of abuse against intimate partner
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of intimate partner violence
Endpoint domain: Adverse events/effects
Primary endpoint: Radiographic Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in average daily pain NRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of caregivers using the universal strategy
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Number of Participants With MRD-Negative Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech recognition score (word score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of chronic postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of Milk Supply
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of local recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: AUC: Area under the plasma concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waist Circumference Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose received by the bladder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent pain after breast cancer treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Locally recurrent free survival
Endpoint domain: Mortality/survival
Primary endpoint: Area under the plasma concentration-time curve from time zero to the last quantifiable concentration post-dose (AUC0→t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate (OOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on the Breast Cancer Treatment Outcome Scale (BCTOS) Cosmesis
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Distance in the staple line till the dentate line of the anal canal in cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of R1 resections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction of total GERD-HRQL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Serious, device-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants that presented seroconversion post injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean of Hemagglutination-inhibition titre post first study injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: White matter hyperintensities volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Degree of Cognitive Decline
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Knee cartilage measured by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Alveolar socket filled by new bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: HIV-1 seroconversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of grade 3+ radiation therapy oncology central nervous system toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Progression Free Survival (PFS) at four months
Endpoint domain: Mortality/survival
Primary endpoint: Assessment of success or failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of the VPAC assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in protein carbonyls in red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in high sensitivity C-reactive protein in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in white blood cell count in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PrU Incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Completion Rate for Randomised Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Peak Knee Extension Moment Symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Subjective Effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Patients With Loss of Asthma Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change of handgrip strength (HGS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of diaphragm thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life- SF-36(Taiwan version)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Length velocity at 6 months of infant's age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects attaining target LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vertigo Score (VS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Ecarin Clotting Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Diluted Thrombin Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor and sensory nerve conduction velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: f-wave in neutral position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Absolute Reduced Limb Volume Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Model predicted treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologically determined treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum creatinine (Scr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of Good Functional Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Neurological measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AUClast of Firsocostat, GS-834773, and Fenofibric Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of Firsocostat, GS-834773, and Fenofibric Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Firsocostat, GS-834773, and Fenofibric Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of Pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Persistence of Pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Myalgia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline serum BDNF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from contrast sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from functional magnetic resonance imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macrophage activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the frequency of circulating cells with aldehyde dehydrogenase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Area under the Curve - Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Mepolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve (AUC[0-t]) of Mepolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve (AUC[0-inf]) of Mepolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: LF/HF ratio of heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Montgomery and Asberg Depression Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in oxyhemoglobin and deoxyhemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Systemic inflammation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endotoxemia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease progression in the previously affected foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Condition specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of emergency dialysis patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Persistent post-surgical pain (PPSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate-to-severe PPSP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences From Baseline in Penetration Aspiration Scale (PAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotection rate to HBV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient's knowledge on care and maintenance of dental implants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in total score of Saint George's Respiratory Questionnaire (SGRQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Association between Atrial Fibrillation and Sleep Apnea severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: HPV16 and HPV18 prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Olfactory Function Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Function Change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Remaining wound area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall Survival (OS) For High-risk Acute Myeloid Leukemia (AML) Participants
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival (OS) For High-risk Myelodysplastic Syndromes (MDS) Participants
Endpoint domain: Mortality/survival
Primary endpoint: Event-free Survival (EFS) For High-risk Acute Myeloid Leukemia (AML) Participants
Endpoint domain: Mortality/survival
Primary endpoint: Ricker sedation-agitation scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nursing activity score (NAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital signs (Mean arterial pressure, heart rate, pulse oxygen saturation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Comparison of complications during the PACU period
Endpoint domain: Adverse events/effects
Primary endpoint: Comprehensive satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life